Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.62 |
| ▸ | RAB9A | P51151 | 1/20 | 0.62 |
| ▸ | POLB | P06746 | 4/20 | 0.61 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.60 |
| ▸ | GLA | P06280 | 1/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.58 |
| ▸ | MEN1 | O00255 | 3/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.58 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.57 |
| ▸ | HTR7 | P34969 | 2/20 | 0.56 |
| ▸ | GAA | P10253 | 1/20 | 0.56 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.56 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3329899 | 0.91 | NPC1 (0.70) | NPC1RAB9APOLBSMN1; SMN2GLA | |
| SCHEMBL13161963 | 0.88 | NPC1 (0.65) | NPC1RAB9APOLBSMN1; SMN2GLA | |
| SCHEMBL31188489 | 0.84 | NPC1 (0.56) | NPC1POLBSMN1; SMN2KMT2AMEN1 | |
| SCHEMBL31188531 | 0.84 | NPC1 (0.56) | NPC1POLBSMN1; SMN2KMT2AMEN1 | |
| SCHEMBL13634474 | 0.83 | KMT2A (0.66) | NPC1RAB9APOLBSMN1; SMN2GLA | |
| SCHEMBL457993 | 0.81 | NPC1 (0.84) | NPC1RAB9APOLBSMN1; SMN2GLA | |
| SCHEMBL28249225 | 0.81 | HTR7 (0.63) | NPC1RAB9APOLBSMN1; SMN2KMT2A | |
| SCHEMBL358264 | 0.81 | CTSL (0.63) | NPC1RAB9APOLBSMN1; SMN2KMT2A | |
| SCHEMBL10274561 | 0.81 | CTSL (0.63) | NPC1RAB9APOLBSMN1; SMN2KMT2A | |
| SCHEMBL20477092 | 0.80 | TAS1R3 (0.56) | NPC1RAB9APOLBSMN1; SMN2GLA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8242129-B2 | 6-phenylpyrimidinones as PIM modulators | EXELIXIS, INC. (US) | 2012-08-14 | — | — | US | claimed |
| US-20100135954-A1 | 6-Phenylpyrimidinones as PIM Modulators | EXELIXIS, INC. (US) | 2010-06-03 | — | — | US | claimed |
| EP-2074103-A1 | 6-PHENYLPYRIMIDINONES AS PIM MODULATORS | Exelixis, Inc. (US) | 2009-07-01 | — | — | EP | claimed |
| WO-2008133955-A1 | 6-PHENYLPYRIMIDINONES AS PIM MODULATORS | EXELIXIS, INC. (US) | 2008-11-06 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100135954-A1 | 6-Phenylpyrimidinones as PIM Modulators | PIM1, PIM2, PIM3 | NPC1 2501/4885RAB9A 2601/4885POLB 4306/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.